Onesource Specialty Pharma Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Onesource Specialty Pharma (NSE: ONESOURCE) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Onesource Specialty Pharma trading at Rs 72 — against a 52-week high of Rs 128 and a 1-year return of -35% — the Q4 FY26 results will be a key event for investors tracking the Pharma/CDMO sector.

Available data and public filings suggest Q4 FY26 revenue in the range of Rs 55–68 Cr, with PAT of Rs 4–7 Cr and margins around EBITDA 10–14%. This article covers the Onesource Specialty Pharma Q4 results 2026 date, earnings estimates based on public data, five performance factors, five risks, and answers to commonly searched investor questions.

Get free investment predictions on Univest.

Onesource Specialty Pharma Q4 Results 2026 Date

Onesource Specialty Pharma is expected to announce its Q4 FY26 results in May 2026 (Expected). The board of directors will meet to approve audited financial statements for the quarter ended March 31, 2026, and consider any dividend recommendation. At a CMP of Rs 72, investors will watch this announcement for FY27 business outlook.

Why This Quarter Matters

Q4 FY26 is the final quarter of the financial year — it determines full-year FY26 performance and sets the FY27 earnings base. For Onesource Specialty Pharma, which operates in the Pharma/CDMO segment, Q4 is seasonally important for order execution, collections, and revenue recognition. The results will provide investors with a clearer picture of the company’s operational trajectory.

At a 1-year return of -35%, Onesource Specialty Pharma’s Q4 FY26 results and management commentary on FY27 will be critical for investor sentiment. Positive operating metrics — whether revenue growth, margin improvement, or business pipeline — could help the stock recover from current levels toward its 52-week high of Rs 128.

Onesource Specialty Pharma Q4 FY26 Earnings Estimates

Onesource Specialty Pharma Q4 FY26 Estimates at a Glance | Source: NSE/BSE, Company IR

Access research and stock insights on Univest.

Based on Q3 FY26 actuals and available public data, Q4 FY26 estimates for Onesource Specialty Pharma point to revenue of Rs 55–68 Cr and PAT of Rs 4–7 Cr, with margins expected around EBITDA 10–14%. These estimates incorporate Q4 seasonal trends and the company’s recent operating trajectory. Note that Onesource Specialty Pharma has limited institutional analyst coverage — investors should verify figures independently.

Investors should pay particular attention to revenue quality, working capital trends, and management commentary on business pipeline for FY27. Given limited broker coverage, independent research and primary due diligence are especially important for this company.

Screen Onesource Specialty Pharma on the Univest Screener for fundamental data.

5 Key Factors That Will Drive Onesource Specialty Pharma Q4 FY26 Performance

Revenue Growth and Business Recovery

Onesource Specialty Pharma’s Q4 FY26 revenue estimate of Rs 55–68 Cr reflects business recovery momentum in the Pharma/CDMO segment. Q4 is typically a strong quarter for most Indian companies due to year-end order push, seasonal demand, and government spending acceleration. Onesource Specialty Pharma’s ability to capitalise on Q4 tailwinds will depend on its operational execution, client retention, and capacity utilisation levels going into the quarter.

Margin Improvement and Operating Leverage

Onesource Specialty Pharma’s margin estimate of EBITDA 10–14% reflects expected improvement from Q3 levels as fixed costs get absorbed over a larger revenue base. Micro and small-cap companies often see disproportionate margin improvement when revenues scale even modestly. Management’s cost discipline — particularly on employee expenses and overheads — will determine the extent of margin recovery in Q4 FY26.

Working Capital Efficiency

For smaller companies like Onesource Specialty Pharma, working capital management is a critical metric that often differentiates between strong and weak performers within a sector. Q4 FY26 results will reveal debtor days, inventory levels, and cash conversion cycle — all of which impact free cash flow. Improvement in working capital efficiency would indicate better business quality and reduce the need for expensive short-term borrowing.

FY27 Business Pipeline and Growth Visibility

Onesource Specialty Pharma’s management commentary on FY27 business pipeline, new client wins, and strategic initiatives will be as important as the headline Q4 numbers. For smaller companies, forward-looking guidance — even if informal — provides investors with confidence in future earnings trajectory. Any positive commentary on new opportunities, geographic expansion, or product launches would support stock recovery.

Competitive Positioning in Niche Segment

Onesource Specialty Pharma operates in a niche within the Pharma/CDMO sector where specialisation can provide meaningful competitive advantage. Q4 FY26 results will demonstrate whether the company is gaining or losing ground versus competitors. Market share stability, client stickiness, and pricing power are key indicators of competitive health for smaller companies where large-scale data is limited.

5 Risks to Watch in Onesource Specialty Pharma Q4 FY26

Limited Analyst Coverage and Price Discovery Risk

Onesource Specialty Pharma has limited institutional analyst coverage, which means price discovery is less efficient and stock price movements can be exaggerated in both directions. Investors relying on this article should supplement with direct NSE/BSE filing reviews and company investor relations communications before making investment decisions.

Liquidity and Market Depth Risk

As a smaller company, Onesource Specialty Pharma has lower daily trading volumes, which means bid-ask spreads can be wider and large buy/sell orders can move the price significantly. This creates execution risk for investors — both entering and exiting positions — particularly if the Q4 results disappoint and trigger selling pressure.

Macroeconomic and Sector Headwinds

The broader macroeconomic environment — including US tariff impacts on Indian equities, FII outflows, and domestic demand conditions — affects smaller companies disproportionately. Onesource Specialty Pharma’s Pharma/CDMO segment may face sector-specific headwinds that compress revenue and margins below Q4 FY26 estimates if macro conditions deteriorate further.

Financial Reporting Quality and Governance

Smaller listed companies carry inherent governance and financial reporting risks compared to Nifty-500 companies with extensive institutional scrutiny. Investors in Onesource Specialty Pharma should review auditor notes, related-party transactions, and contingent liabilities in the Q4 FY26 annual results carefully before drawing conclusions about financial health.

Funding and Balance Sheet Risk

Smaller companies often have limited access to low-cost capital. Any deterioration in credit conditions, rising interest rates, or banker-imposed covenants could constrain Onesource Specialty Pharma’s ability to fund growth or service existing debt. Balance sheet strength — particularly net debt levels and interest coverage — is a critical watchpoint in Q4 FY26 results.

Onesource Specialty Pharma Share Price and Data Summary

Onesource Specialty Pharma Share Price Snapshot | Source: NSE/BSE

Onesource Specialty Pharma is trading at Rs 72 as of early April 2026, against a 52-week high of Rs 128 and 52-week low of Rs 55. Market cap stands at Rs 320 Cr. The 1-year return of -35% reflects sector and company-specific conditions. Given limited institutional coverage, investors should review company filings directly on NSE/BSE for the most updated data.

Download the Univest iOS App or Univest Android App to track Onesource Specialty Pharma’s live price and Q4 result alerts.

Conclusion

Onesource Specialty Pharma Q4 FY26 results will reflect the company’s specialty pharma and CDMO business trajectory. At Rs 72, the stock is 44% below its 52-week high. Revenue toward Rs 62 Cr with PAT improvement toward Rs 6 Cr would be positive. ANDA pipeline and export client additions are key long-term catalysts. Conduct independent research given limited institutional coverage. Consult a SEBI-registered advisor before investing.

This content is published by Univest, a SEBI-registered research and advisory platform. All data cited is from publicly available sources including NSE/BSE filings and company investor relations. Past performance is not indicative of future results.

For more Q4 FY26 previews, visit Univest Blogs.

Frequently Asked Questions

What is the Onesource Specialty Pharma Q4 results 2026 date?

Onesource Specialty Pharma Q4 FY26 results are expected in May 2026 (Expected). The board of directors will meet to approve audited results for the quarter ended March 31, 2026.

What is the Onesource Specialty Pharma Q4 FY26 PAT estimate?

Based on available public data, Onesource Specialty Pharma Q4 FY26 PAT is estimated in the range of Rs 4–7 Cr, on revenue of Rs 55–68 Cr and margin of EBITDA 10–14%. These are indicative estimates — actual results may differ.

What is Onesource Specialty Pharma’s share price ahead of Q4 results?

Onesource Specialty Pharma shares are trading at approximately Rs 72 as of early April 2026. The 52-week high is Rs 128 and 52-week low is Rs 55. The one-year return is -35% and market cap stands at Rs 320 Cr.

Will Onesource Specialty Pharma declare a dividend in Q4 2026?

Onesource Specialty Pharma is expected to consider Nil expected at the Q4 FY26 board meeting. The dividend decision will depend on FY26 free cash flow and management’s capital allocation priorities.

Is there institutional analyst coverage on Onesource Specialty Pharma?

Onesource Specialty Pharma has limited institutional analyst coverage given its market cap and listing profile. Investors are advised to review NSE/BSE filings, Screener.in data, and company investor relations pages for due diligence.

What were Onesource Specialty Pharma Q3 FY26 results?

In Q3 FY26, Onesource Specialty Pharma reported revenue of Rs 48 Cr and PAT of Rs 3 Cr, with margins at EBITDA 11.5%. These figures provided the base for Q4 FY26 estimates.

When do Infosys and TCS announce Q4 results 2026?

TCS announced Q4 FY26 results on April 9, 2026 — full preview at TCS Q4 Results 2026. Infosys announced results on April 23, 2026.

Is Onesource Specialty Pharma a good investment ahead of Q4 results?

Onesource Specialty Pharma at Rs 72 is a small/micro-cap stock with limited analyst coverage. Investors should conduct thorough independent research, review company financials on NSE/BSE, and consult a SEBI-registered advisor before making any investment decision.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

Recent Article

Motisons Jewellers Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Motilal Oswal Financial Services Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Moschip Technologies Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Morepen Laboratories Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Morarjee Textiles Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook